OncoMatch/Clinical Trials/NCT05917145
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Is NCT05917145 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies WSD0628 for glioblastoma.
Treatment: WSD0628 — The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Allowed: IDH1 mutation
Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification)
Allowed: IDH2 mutation
Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification)
Allowed: IDH1 wild-type
Glioblastoma, IDH-wildtype
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — glioma
Disease progression after previous treatment for glioma with radiation and chemotherapy
Must have received: chemotherapy — glioma
Disease progression after previous treatment for glioma with radiation and chemotherapy
Cannot have received: radiation therapy
Radiation therapy <= 26 weeks prior to registration (including gamma tiles)
Cannot have received: chemotherapy
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: immunotherapy
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: investigational drug
Chemotherapy, immunotherapy, or any investigational drug <= four weeks prior to registration
Cannot have received: alkylating agent (carmustine, lomustine)
carmustine (BCNU) or lomustine (CCNU) <= six weeks prior to registration
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; Leukocytes ≥3.0 x 10^9/L; ANC ≥1500/mm3 or 1.5 x 10^9/L; Platelet count ≥100,000/mm3 or 100 x 10^9/L
Kidney function
Calculated creatinine clearance ≥45 ml/min using Cockcroft-Gault formula
Liver function
Total bilirubin ≤1.5 x ULN and <3 mg/dL for patients with Gilbert's disease; ALT and AST ≤3 x ULN
Cardiac function
PT/INR/aPTT ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy
The following laboratory values obtained ≤15 days prior to registration: Hemoglobin ≥9.0 g/dL; Leukocytes ≥3.0 x 10^9/L; ANC ≥1500/mm3 or 1.5 x 10^9/L; Platelet count ≥100,000/mm3 or 100 x 10^9/L; Total bilirubin ≤1.5 x ULN and <3 mg/dL for patients with Gilbert's disease; ALT and AST ≤3 x ULN; PT/INR/aPTT ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy; Calculated creatinine clearance ≥45 ml/min using Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify